ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Esperion Therapeutics, Inc. ?
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Operating profit has grown by an annual rate 8.36% of over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -2.53
2
The company has declared negative results in Mar'2025 after 7 consecutive positive quarters
- NET SALES(HY) At USD 147.38 MM has Grown at -30.34%
- NET PROFIT(HY) At USD -53.18 MM has Grown at -201.62%
- RAW MATERIAL COST(Y) Grown by 17.34% (YoY)
3
Risky - Negative EBITDA
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 43.58%, its profits have fallen by -33.9%
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Esperion Therapeutics, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Esperion Therapeutics, Inc.
16.62%
0.30
88.87%
S&P 500
13.22%
0.61
20.17%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
4.41%
EBIT Growth (5y)
8.36%
EBIT to Interest (avg)
-2.53
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.12
Sales to Capital Employed (avg)
1.20
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
80.40%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-0.57
EV to EBIT
-18.06
EV to EBITDA
-18.10
EV to Capital Employed
14.10
EV to Sales
2.78
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-78.07%
ROE (Latest)
Negative BV
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend10What is working for the Company
DEBT-EQUITY RATIO
(HY)
Lowest at -118.13 %
INVENTORY TURNOVER RATIO(HY)
Highest at 1.04 times
NET SALES(Q)
Highest at USD 82.39 MM
OPERATING PROFIT(Q)
Highest at USD 7.12 MM
OPERATING PROFIT MARGIN(Q)
Highest at 8.64 %
PRE-TAX PROFIT(Q)
At USD -12.72 MM has Grown at 48.22%
NET PROFIT(Q)
At USD -12.72 MM has Grown at 48.22%
EPS(Q)
Highest at USD -0.06
-19What is not working for the Company
NET SALES(HY)
At USD 147.38 MM has Grown at -30.34%
NET PROFIT(HY)
At USD -53.18 MM has Grown at -201.62%
RAW MATERIAL COST(Y)
Grown by 17.34% (YoY
CASH AND EQV(HY)
Lowest at USD 200.69 MM
INTEREST(Q)
Highest at USD 20.49 MM
Here's what is working for Esperion Therapeutics, Inc.
Net Sales
Highest at USD 82.39 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Net Sales
At USD 82.39 MM has Grown at 26.95%
over average net sales of the previous four periods of USD 64.89 MMMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Operating Profit
Highest at USD 7.12 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (USD MM)
Operating Profit Margin
Highest at 8.64 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Pre-Tax Profit
At USD -12.72 MM has Grown at 48.22%
over average net sales of the previous four periods of USD -24.58 MMMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
At USD -12.72 MM has Grown at 48.22%
over average net sales of the previous four periods of USD -24.58 MMMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
EPS
Highest at USD -0.06
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Debt-Equity Ratio
Lowest at -118.13 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Inventory Turnover Ratio
Highest at 1.04 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its inventory faster
Inventory Turnover Ratio
Here's what is not working for Esperion Therapeutics, Inc.
Interest
Highest at USD 20.49 MM
in the last five periods and Increased by 5.43% (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (USD MM)
Cash and Eqv
Lowest at USD 200.69 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
Raw Material Cost
Grown by 17.34% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
